January 12, 2021

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

Today it was announced that POINT has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.

December 9, 2020

POINT Biopharma Announces New Board Appointments

POINT today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors.

November 10, 2020

Announcing licensing and partnership for canSEEK™ pan-cancer targeting technology

POINT today announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University...

October 13, 2020

POINT Biopharma Presents at 2020 BIO Investor Forum

POINT Biopharma Inc. announces its CEO Dr. Joe McCann will present at the 2020 BIOInvestor Forum.

August 25, 2020

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits...